Drug improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopath …

Sumary of Drug improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy:

  • Valsartan, an angiotensin II receptor blocker drug, delayed disease progression and improved cardiac structure and function in patients with early-stage hypertrophic cardiomyopathy, according to results from a recent clinical trial published in Nature Medicine.
  • In addition, if we can delay disease progression, this may ultimately mean that we can significantly impact the risk of sudden cardiac death in this population.
  • Therefore, therapies that slow disease progression and address its underlying causes are greatly needed, and the drug valsatran, an angiotensin II receptor blocker, had been suggested as a solution to prevent the development of hypertrophy altogether.
  • Related StoriesPrevious work had demonstrated that a similar angiotensin II receptor drug prevented the development of hypertrophy when given to mouse models with early-stage disease, suggesting that valsartan may also be an effective treatment.
  • In the current clinical trial, more than 170 participants between the ages of 8 and 45 years old who were diagnosed with early-stage hypertrophic cardiomyopathy were randomized to receive either valsartan or a placebo for two years.
  • Overall, participants in the valsartan group demonstrated improved cardiac structure and function compared to the placebo group.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close